Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients
Juvenile Idiopathic Arthritis
About this trial
This is an interventional treatment trial for Juvenile Idiopathic Arthritis
Eligibility Criteria
Inclusion Criteria: Pediatric patients (<16 years old) Diagnosed with active JIA according to the American College of Rheumatology (ACR) 2019 guideline. Patients with peripheral oligo or polyarthritis. With more than 6-month disease duration Participants who have inadequate response to at least one first line standard therapy. Patients who have been receiving a stable treatment regimen for the past 3 months Exclusion Criteria: Patients with active systemic JIA Patients presenting with complications (such as amyloidosis, uveitis, or glomerulonephritis) Patients with other chronic autoimmune disease.
Sites / Locations
- Pediatric Allergy, Immunology, Rheumatology Clinic, Children's Hospital, Ain Shams University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Coenzyme Q10 Group
Control Group
Patients will receive their JIA standard treatment plus 100 mg Coenzyme Q10 capsules daily for 3 months.
Patients will receive their standard JIA treatment plus placebo